InvestSMART

Anatara Lifesciences Ltd (ASX:ANR)

ALERT: Price-sensitive ASX Announcement for ANR
Current share price for ANR : $0.010 0 (0%)+
Announcement
Release
25 Feb 2026 1:04PM
Price at Release
$0.010
Full Release
download
Summary
Anatara Lifesciences Ltd reported a decrease in revenue and an improved net loss for the half-year ended 31 December 2025. Revenue from ordinary activities was down by 66% compared to the previous year, while the net loss decreased by 56% to $514,975. The company's Anti-Obesity Project showed promising preliminary results with its AOC compound, which demonstrated statistically significant activity in weight management during pre-clinical studies. However, there were delays in completing Mechanism of Action studies due to an international unavailability of a testing kit. The GaRP product for gastrointestinal health also made progress, with successful completion of the GaRP-IBS Phase II trial. During the period, Anatara completed a capital raising of A$1.2 million and strengthened its board with new appointments. The company emphasized its focus on projects addressing unmet medical needs in gastrointestinal health and other sectors.
Key Points
  • Revenue from ordinary activities decreased by 66% to $177,564.
  • Net loss after tax decreased by 56% to $514,975.
  • The Anti-Obesity Project's compound AOC showed significant activity in pre-clinical studies.
  • Delays in Mechanism of Action studies due to international unavailability of a testing kit.
  • Successful GaRP-IBS Phase II trial completion.
  • Completed a capital raising of A$1.2 million.
  • Focused on unmet medical needs in gastrointestinal health.
  • Cash at the end of the half year was $1.085 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.